In Silico Screening of BiTE Molecule Targeting CD22 and T-Cell Receptor Complex for Acute Lymphoblastic Leukemia

This research presents a fully in silico pipeline for engineering a Bispecific T-Cell Engager by identifying and validating scFv antibodies that target CD22 and the T-cell receptor for acute lymphoblastic leukemia therapy.

Posted by buchanle on Wednesday, June 3rd, 2026 in May 2026, Acute Lymphoblastic Leukemia, Bispecific T-Cell Engager, Cancer Cell Hypoxia, CD22 Receptor, T-Cell Receptor

Read more